Sherry Bass, OD
Optometrist · New York, NYNPI 1104826536
Payments from drug & device makers
Across 28 payments — averaging $255.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Haag-streit USA, Inc.$5K
- Intuitive Surgical$346
- Tarsus Pharmaceuticals, Inc.$326
- Alcon$284
- Bausch & Lomb Americas Inc.$166
- Harrow Eye, LLC$144
- plus $450 from 7 others
What the payments were for
- Consulting fees$1,00014%
- Travel & lodging$6409%
- Food & beverage$1,51521%
- Education$4,00056%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Haag-streit USA, Inc. | 6 | $5,438 |
| Intuitive Surgical | 2 | $346 |
| Tarsus Pharmaceuticals, Inc. | 6 | $326 |
| Alcon | 2 | $284 |
| Bausch & Lomb Americas Inc. | 3 | $166 |
| Harrow Eye, LLC | 2 | $144 |
| Spark Therapeutics, Inc. | 1 | $123 |
| Regeneron Healthcare Solutions, Inc. | 1 | $112 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $105 |
| Sun Pharmaceutical Industries Inc. | 1 | $38 |
| Dompe US, Inc. | 1 | $29 |
| Glaukos Corporation | 1 | $28 |
| LKC Technologies, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$338
- XDEMVY$268
- Hydrus Microstent$130
- LUXTURNA$123
- MIEBO$118
- EYLEA$112
- VEVYE$111
How this compares
$7,155 in reported general payments places this provider in the 95th percentile of 2,743 optometrist providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 21 | $18,468 |
| RhopressaNetarsudil Mesylate | 20 | $9,126 |
| Brimonidine Tartrate | 40 | $1,722 |
| Latanoprost | 124 | $1,453 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 50 | $971 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 13 | $773 |
| Dorzolamide Hcl | 22 | $505 |
Paid to pharmacies, not to this prescriber.
Other optometrist in New York
- George ZikosNew York$1M
- Irene FrantzisNew York$663K
- Daphne AmbroseNew York$509K
- Susan ResnickNew York$463K
- Denise WhittamNew York$343K
- Jennifer TsaiNew York$275K
- Sophia VisanjiNew York$233K
- Danielle IaconoNew York$206K
- Jason ComptonNew York$197K
- John RobilottoNew York$155K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.